Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CORRESPONDENCE

A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Nature Medicine 28, 1983-1984 (2022)

doi: https://doi.org/10.1038/d41591-022-00077-1

Author contributions

L.B.L.N., J.G. and O.L. are the principal investigators of the study and wrote the manuscript. L.B.L.N. prepared the first draft. L.M., C.D. and J.K.M. designed the methodology of the protocol and edited the manuscript. C.D., E.T., T.S., B.A., J.K.W., D.M. and X.L. oversaw the analysis of data and biological samples of the study and edited the manuscript. C.T., A.T., I.M.O.P., E.T., A.R. and L.R. oversaw the management and coordination responsibility of the research. All authors reviewed the manuscript.

Competing interests

L.B.L.N. has received personal fees as a speaker or consultant from Sanofi and Pfizer. O.L. has received personal fees from Sanofi Pasteur; grants, personal fees, and non-financial support from Pfizer, Janssen, and Sanofi Pasteur–Merck Sharp & Dohme; and grants and non-financial support from GlaxoSmithKline. J.G. has received research grants from Gilead Sciences and Merck Sharp & Dohme and personal fees from Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme, Janssen, Theratechnologies and AstraZeneca. T.S. has received unrestricted research grants from AstraZeneca, Bayer, Boehringer, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Novartis and Sanofi and personal fees from Ablative Solutions, Air Liquide, AstraZeneca, Novartis, 4 living Biotech and Sanofi, for participation on Advisory or data safety monitoring boards, and from Servier and Novartis, for lectures.

References

  1. Petersen, E. et al. Infect. Dis. Clin. North Am. 33, 1027–1043 (2019).

    Google Scholar 

  2. World Health Organization. https://www.who.int/emergencies/disease-outbreak-news/item/2022–DON385 (21 May 2022).

  3. Reed, K.D. et al. N. Engl. J. Med. 350, 342–350 (2004).

    Google Scholar 

  4. Adler, H. et al. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00228-6 (2022).

  5. Rao, A.K. et al. MMWR Morb. Mortal. Wkly. Rep. 71, 734–742 (2022); https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.htm

  6. Pittman, P.R. et al. N. Engl. J. Med. 381, 1897–1908 (2019).

    Google Scholar 

  7. Hatch, G.J. et al. J. Virol. 87, 7805–7815 (2013).

    Google Scholar 

  8. UK Health Security Agency. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1083791/Recommendations-for-pre-and-post-exposure-vaccination-during-a-monkeypox-incident-17-june-2022.pdf (17 June 2022).

  9. Keckler, M.S. et al. Vaccines 8, 396 (2020).

    Google Scholar 

  10. Santé Publique France. https://www.santepubliquefrance.fr/content/download/437302/file/def_cas_CAT_monkeypox_19052022.pdf (2022).

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links